• Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. First prescription of combined oral contraception. London (UK): Faculty of Family Planning and Reproductive Health Care; 2007 Jan. 21 p. [186 references]

Definitions of the grades of recommendation, based on levels of evidence (A-C, Good Practice Point), are provided at the end of the "Major Recommendations" field.

Evidence-Based Information for Clinicians

Medical History Before a First Prescription of Combined Oral Contraception (COC)

1. In order to advise on eligibility for COC use, clinicians should take a clinical history including: medical conditions (past and present), drugs use (prescription, non-prescription and herbal remedies) and family history (Good Practice Point).
2. When considering a first prescription of COC, clinicians should specifically enquire about migraine and cardiovascular risk factors (smoking, obesity, hypertension, thrombophilia, previous venous thromboembolism and hyperlipidaemia) (Good Practice Point).
3. User preference and individual concerns about COC use should be addressed (Good Practice Point).

   (See Table 2 of the original guideline document for the UK Medical Eligibility Criteria [UKMEC] for combined oral contraceptive use.)

Age

4. COC can be used from the menarche to age 50 years if there are no other risk factors (Grade C).

Smoking

5. Clinicians should be aware that there is a very small increased risk of myocardial infarction (MI) with current COC use in non-smokers which increases further for smokers (Grade B).
6. Use of COC by women aged >35 years who smoke is not recommended (Grade B).
7. Use of COC may be considered by women aged >35 years who have stopped smoking for >1 year (Grade C).

Obesity

8. Use of COC by women with a body mass index (BMI) >35 is associated with an increased risk of myocardial infarction (MI) and venous thromboembolism (VTE) and is not generally recommended (Grade B).

Hypertension

9. Use of COC is not generally recommended when blood pressure is consistently >140 mmHg systolic and/or >90 mmHg diastolic (Grade C).

Venous Thromboembolism

10. Use of COC by women with a personal history of VTE or known thrombogenic mutations is not recommended (Grade C).
11. Clinicians should be aware that the relative risk of VTE with COC use can increase up to five-fold, but in absolute terms the risk is still very low (Grade B).
12. A thrombophilia screen is not recommended routinely before prescribing COC (Grade C).
13. For women with a family history of VTE, a negative thrombophilia screen does not necessarily exclude all thrombogenic mutations (Grade C).
14. The interpretation of a thrombophilia screen should be undertaken in consultation with a haematologist or other expert and in combination with a detailed family history (Good Practice Point).

Stroke

15. Clinicians should be aware that there is a very small increase in the absolute risk of ischaemic stroke with COC use (Grade B).

Migraine

16. Use of COC by women of any age who have migraine with aura is not recommended (Grade B).
17. Use of COC by women >35 years of age who have migraine without aura is not generally recommended (Grade B).

Breast Cancer

18. Clinicians should be aware that any increased risk of breast cancer with COC use is likely to be small, is in addition to background risk, and is reduced to no increased risk 10 years after stopping COC use (Grade B).

Cervical Cancer

19. Clinicians should be aware that there may be a very small increase in the risk of cervical cancer with COC use, which increases with increasing duration of use (Grade B).

Potential Drug Interactions

20. Clinicians should consider the possibility of drug interactions when prescribing COC (Good Practice Point).
21. Liver enzyme-inducing drugs may reduce the efficacy of COC; therefore, if they are to be used long term, alternative contraceptives that are unaffected by enzyme-inducing drugs should be considered (Grade C).
22. If, after counselling, women using liver enzyme-inducing drugs still wish to use COC then a regimen with at least 50 micrograms EE should be used. In addition, barrier contraception is recommended while taking the liver enzyme-inducers and for 28 days after they are stopped (Good Practice Point).
23. A woman taking long-term non-liver enzyme-inducing antibiotics (≥3 weeks) does not require additional contraceptive protection when starting COC (Grade C).
24. Women using COC who are prescribed a short course (<3 weeks) of non-liver enzyme-inducing antibiotics should be advised to use additional contraceptive protection while taking the antibiotic and for 7 days after the antibiotic is stopped (Grade C).

Potential Non-Contraceptive Benefits to Be Considered

Dysmenorrhoea and Menorrhagia

25. Clinicians should be aware that menstrual pain and blood loss may be reduced with COC use (Grade C).

Ovarian Cysts

26. Clinicians should be aware that the incidence of functional ovarian cysts and benign ovarian tumours is reduced with COC use (Grade B).

Ovarian and Endometrial Cancer

27. Clinicians should be aware that there is at least a 50% reduction in the risk of ovarian and endometrial cancer with COC use which continues for 15 or more years after stopping (Grade B).

Colorectal Cancer

28. Clinicians should be aware that COC use is associated with a reduction in the risk of colorectal cancer (Grade B).

Acne Vulgaris

29. Clinicians should be aware that COCs can improve acne vulgaris (Grade A).

Other Relevant Information

Weight Gain

30. Clinicians should be aware that there is no evidence of additional weight gain due to COC use (Grade A).

Bleeding Patterns

31. Clinicians should be aware that unscheduled bleeding can occur with COC use but in the absence of missed pills, vomiting within 2 hours of pill taking, severe diarrhoea or drug interactions it is not a measure of efficacy (Grade B).
32. Clinicians may wish to give women advice to alter the timing of the withdrawal bleeds but should be aware that this use is outside the terms of the product licences (Good Practice Point).

Which Examinations Are Needed Before a First Prescription of COC?

33. A blood pressure recording should be documented for all women prior to a first prescription of COC (Grade C).
34. Body mass index (BMI) should be documented for all women prior to a first prescription of COC (Good Practice Point).

When Can COC Be Started?

35. Ideally COC should be started on the first day of menstruation but can be started up to and including Day 5 of the cycle without the need for additional contraceptive protection (Grade C).
36. COC can be started at any other time in the cycle if it is reasonably certain the woman is not pregnant but additional contraceptive protection, such as condoms, is required for the first 7 days (Grade C).

Table. When to Start Combined Oral Contraception (COC) in Different Circumstances

COC, combined oral contraception; IUD, intrauterine device; IUS, intrauterine system; VTE, venous thromboembolism.

Which Pill Is Suitable for Women Being Given a First Prescription of COC?

37. A monophasic COC containing 30 micrograms EE with norethisterone or levonorgestrel is a suitable first pill (Grade C).

What Follow-Up Arrangements Are Appropriate for Women Being Given a First Prescription of COC?

38. A follow-up visit 3 months after a first prescription of COC allows an assessment of blood pressure, further instruction and assessment of any problems (Good Practice Point).
39. In the absence of special problems, women can be given up to 12 months' supply of COC at follow-up and encouraged to return at any time if problems arise (Grade C).

Evidence-Based Information for Women

What Information Should Be Given to All Women When Receiving a First Prescription of COC?

Potential Harms and Benefits

40. At first prescription of COC all women should be informed that:
    • COC use is safe for the majority but can be associated with rare but serious harms
    • There is a small increase in the risk of blood clots with COC use
    • There is a very small increase in the risk of heart attack and stroke with COC use
    • Any increased risk of breast cancer is likely to be small and returns to no increased risk 10 years after stopping COC
    • There may be a very small increase in the risk of cervical cancer that increases with increasing duration of use
    • The risk of ovarian and endometrial cancer is halved with COC use and this continues for at least 15 years after stopping (Grade B).

How To Take the Pill

41. Women should be advised to start COC on the first day of menstruation but it can be started up to and including Day 5 of the cycle without the need for additional contraceptive protection (Grade C).
42. Women can start COC at other times in the menstrual cycle if is reasonably certain that they are not pregnant but additional contraceptive protection is required for the first 7 days (Grade C).
43. Women should be encouraged to take one pill every day, at around the same time, for 21 consecutive days (Grade C).
44. Women should be advised that if all pills are taken consistently and correctly a COC is >99% effective at preventing pregnancy, even during the routine seven hormone-free days (Grade B).
45. Missing pills is not encouraged but women can be reassured that if one pill in the packet is missed at any time then contraceptive protection is not lost. If more pills are missed and they are unsure what to do they should seek help (Grade C).

Situations Where Efficacy May Be Reduced

46. Women should be advised that if vomiting occurs within 2 hours of taking COC another pill should be taken as soon as possible (Grade C).
47. Women should be informed that if they are prescribed antibiotics (non-liver enzyme-inducing) then additional contraceptive protection such as condoms should be used during the treatment and for 7 days after the antibiotic is stopped. If fewer than seven active pills are left in the pack after antibiotics are finished the woman should omit the pill-free interval (or discard any inactive pills). After using the same antibiotic for ≥3 weeks additional contraception is no longer required (Grade C).

Other Information

48. Women should be encouraged to continue with the first COC for at least 3 months before considering an alternative (Good Practice Point).
49. Women should be given information on symptoms, which should prompt immediate medical consultation such as warning signs of VTE and new headache (Good Practice Point).
50. Women can be advised about practising safer sex with the use of condoms in addition to COC (Good Practice Point).
51. Women should be provided with appropriate written and verbal instructions regarding rules for missed pills, vomiting within 2 hours of taking a pill, severe diarrhoea, the use of new medication and when to seek help (Good Practice Point).

Definitions

Grades of Recommendation based on levels of evidence as follows:

A: Evidence based on randomised controlled trials (RCTs)

B: Evidence based on other robust experimental or observational studies

C: Evidence is limited but the advice relies on expert opinion and has the endorsement of respected authorities

Good Practice Point: Where no evidence exists but where best practice is based on the clinical experience of the multidisciplinary group

An algorithm is provided in the original guideline document on advice for women missing combined oral contraceptive pills.

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations" field).

• Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. First prescription of combined oral contraception. London (UK): Faculty of Family Planning and Reproductive Health Care; 2007 Jan. 21 p. [186 references]

Not applicable: The guideline was not adapted from another source.

2003 Oct (revised 2007 Jan)

Faculty of Sexual and Reproductive Healthcare - Professional Association

Faculty of Sexual and Reproductive Healthcare

Clinical Effectiveness Committee

Clinical Effectiveness Unit (CEU): Dr Susan Brechin (Senior Lecturer/Director of the CEU); Gillian Stephen (ECU Research Assistant), and Lisa Allerton (CEU Research Assistant)

Clinical Effectiveness Committee: Dr Suzanne Burgess (Senior Doctor in Reproductive Health Care, Croydon Primary Care Trust), Dr Joan Burnett (Associate Specialist, Square 13 Contraceptive and Reproductive Health Service, Aberdeen), Dr Lesley Craig (Associate Specialist, Square 13 Contraceptive and Reproductive Health Service, Aberdeen), Dr Rachel D'Souza (Associate Specialist, Margaret Pyke Centre, London), Dr Judith Graham (Staff Grade, The Sandyford Initiative, Glasgow; Faculty of Family Planning Education Committee Member), Professor Philip Hannaford (NHS Grampian Professor of Primary Care, University of Aberdeen), Dr Connie Smith (Co-Director, Westside Contraceptive Services, London) and Dr Sarah Wallage (Consultant in Sexual and Reproductive Health Care, Aberdeen)

Not stated

None available

This NGC summary was completed by ECRI on July 5, 2005. This summary was updated by ECRI Institute on May 13, 2008.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.